Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.360
-0.120 (-4.84%)
May 7, 2026, 12:03 PM EDT - Market open
CNTB Revenue
In the year 2025, Connect Biopharma Holdings had annual revenue of $64.00K, down -99.75%.
Revenue (ttm)
$64.00K
Revenue Growth
-99.75%
P/S Ratio
2,190.20
Revenue / Employee
$1,000
Employees
64
Market Cap
133.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.00K | -25.97M | -99.75% |
| Dec 31, 2024 | 26.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Jan 1, 2022 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 66.80M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Equillium | 4.39M |
| Alps Group | 3.74M |
| Kazia Therapeutics | 1.27M |
| InflaRx | 34.44K |
CNTB News
- 14 days ago - Connect Biopharma announces enrollment in Seabreeze STAT study - TheFly
- 14 days ago - Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - GlobeNewsWire
- 5 weeks ago - Connect Biopharma director buys $4.0M in common stock - TheFly
- 5 weeks ago - Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Connect Biopharma Holdings Transcript: Study result - Transcripts
- 5 weeks ago - Connect Biopharma announces results from rademikibart study - TheFly
- 5 weeks ago - Connect Biopharma Announces $20.2 Million Private Placement Financing - GlobeNewsWire
- 5 weeks ago - Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewsWire